Horizon Pharma Plc (HZNP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH243700D
- Pages: 102
- November 2018
- Total Views:1167
- Region : Europe
- GlobalData
- Equity Research Report
Details
Summary
Horizon Pharma plc (Horizon Pharma) is a pharmaceutical company which develops and commercializes medical products for the treatment of pain, arthritis and inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. The company's marketed products include Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid 2%, Procysbi, Quinsair, Ravicti, Rayos and Vimovo. Horizon Pharma provides products and services to patients and healthcare professionals in the US. The company operates through offices in Illinois, California, Switzerland, the Netherlands and Germany. Horizon Pharma is headquartered in Dublin, Ireland.
Horizon Pharma Plc (HZNP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Horizon Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Horizon Pharma Acquires Worldwide Rights to Interferon Gamma-1b from Boehringer Ingelheim for USD28.2 Million 15
Horizon Pharma Acquires US Rights to Pennsaid 2% from Nuvo Research for USD45 Million 16
Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For USD 51 Million 18
Vidara Therapeutics International Acquires Actimmune From InterMune For USD 55 Million 20
Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 22
Venture Financing 23
River Vision Development Raises USD5 Million in Financing Round 23
River Vision Development Raises USD5.3 Million in Financing Round 24
River Vision Development Raises USD6 Million in Financing Round 25
River Vision Development Raises USD 17 Million In Series A Financing 26
Hyperion Therapeutics Raises USD 15 Million In Series D-II Financing 27
Private Equity 28
Vidara Therapeutics Raises Funds Through Private Equity Financing 28
Partnerships 29
Horizon Pharma Enters into Agreement with XL-protein 29
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 30
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 31
Clinigen Group Partners with Horizon Pharma 32
Horizon Pharma Enters into Agreement with Alliance for Lupus Research 33
Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 34
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 36
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 37
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 38
Licensing Agreements 40
Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 40
Horizon Pharma Enters into Licensing Agreement for Interferon Gamma-1b 41
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 42
Equity Offering 43
Horizon Pharma Raises USD499 million in Public Offering of Shares 43
Hyperion Therapeutics Files Registration Statement For Public Offering Of Securities For USD 150 Million 45
Hyperion Therapeutics Completes Public Offering Of Common Stock For USD 69 Million 46
Horizon Pharma Completes Public Offering Of Units For USD 86 Million 47
Hyperion Therapeutics Completes IPO For USD 57.5 Million 48
Horizon Pharma Completes Private Placement Of Units For USD 51 Million 49
Debt Offering 50
Horizon Pharma Raises USD300 Million in Private Placement of 8.75% Notes Due 2024 50
Horizon Pharma Raises USD475 Million in Private Placement of 6.625% Notes Due 2023 51
Horizon Pharma Raises USD400 Million in Private Placement of 2.5% Senior Notes Due 2022 53
Horizon Pharma Completes Private Placement Of Notes Due 2018 For USD 150 Million 55
Asset Transactions 56
Clinigen Acquires Imukin from Horizon Pharma 56
Horizon Pharma May Sell its Primary Care Drugs Business 57
Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 58
Acquisition 59
Horizon Pharma Acquires River Vision Development 59
Horizon Pharma Acquires Raptor Pharma in Tender Offer 60
Horizon Pharma May Sell Equity Stake in The Company 62
Horizon Pharma Acquires Crealta for USD510 Million 63
Horizon Pharma Acquires Hyperion Therapeutics for USD1.1 Billion 64
Horizon Pharma Acquires Vidara Therapeutics International for USD660 Million in Reverse Acquisition 66
Horizon Pharma Plc-Key Competitors 68
Horizon Pharma Plc-Key Employees 69
Horizon Pharma Plc-Locations And Subsidiaries 70
Head Office 70
Other Locations & Subsidiaries 70
Recent Developments 71
Financial Announcements 71
Nov 07, 2018: Horizon pharma reports third-quarter net sales growth of 20 percent driven by Orphan and Rheumatology net sales growth of 25 percent 71
Aug 08, 2018: Horizon pharma reports record quarterly net sales for orphan and rheumatology segment; increases full-year 2018 adjusted EBITDA guidance; implements new company operating structure to enhance focus on rare diseases 73
May 09, 2018: Horizon Pharma Reports Strong First-Quarter 2018 Orphan and Rheumatology Net Sales Growth 76
Feb 28, 2018: Horizon Pharma Announces Fourth-Quarter and Full-Year 2017 Results 79
Nov 06, 2017: Horizon Pharma Announces Third-Quarter and Year-to-Date 2017 Results 83
Aug 07, 2017: Horizon Pharma Announces Second-Quarter and Year-to-Date 2017 Results and Increases Full-Year 2017 Net Sales and Adjusted EBITDA Guidance 86
May 08, 2017: Horizon Pharma Announces First-Quarter 2017 Results and Revises Full-Year 2017 Net Sales and Adjusted EBITDA Guidance 90
Corporate Communications 93
Nov 30, 2017: Horizon Pharma Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer 93
Sep 11, 2017: Horizon Pharma Names Irina Konstantinovsky Executive Vice President, Chief Human Resources Officer 94
Aug 03, 2017: Horizon Pharma Appoints Pascale Witz and James Shannon, M.D. to Board of Directors 95
Other Significant Developments 96
Sep 27, 2018: The north american pediatric renal trials and collaborative studies and Horizon Pharma announce new long-term cystinosis registry 96
Jun 04, 2018: Horizon Pharma and the National Organization for Rare Disorders (NORD) Illustrate 35 years of Progress in Rare Disease at the Biotechnology Innovation Organization (BIO) International Convention 97
Jan 08, 2018: Horizon Pharma Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments 98
Mar 16, 2017: Horizon Pharma Announces "UCD in Common" for the Urea Cycle Disorder Community 101
Appendix 102
Methodology 102
About GlobalData 102
Contact Us 102
Disclaimer 102
List Of Figure
List of Figures
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
List Of Table
List of Tables
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Horizon Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Horizon Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Horizon Pharma Acquires Worldwide Rights to Interferon Gamma-1b from Boehringer Ingelheim for USD28.2 Million 15
Horizon Pharma Acquires US Rights to Pennsaid 2% from Nuvo Research for USD45 Million 16
Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For USD 51 Million 18
Vidara Therapeutics International Acquires Actimmune From InterMune For USD 55 Million 20
Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 22
River Vision Development Raises USD5 Million in Financing Round 23
River Vision Development Raises USD5.3 Million in Financing Round 24
River Vision Development Raises USD6 Million in Financing Round 25
River Vision Development Raises USD 17 Million In Series A Financing 26
Hyperion Therapeutics Raises USD 15 Million In Series D-II Financing 27
Vidara Therapeutics Raises Funds Through Private Equity Financing 28
Horizon Pharma Enters into Agreement with XL-protein 29
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 30
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 31
Clinigen Group Partners with Horizon Pharma 32
Horizon Pharma Enters into Agreement with Alliance for Lupus Research 33
Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 34
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 36
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 37
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 38
Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 40
Horizon Pharma Enters into Licensing Agreement for Interferon Gamma-1b 41
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 42
Horizon Pharma Raises USD499 million in Public Offering of Shares 43
Hyperion Therapeutics Files Registration Statement For Public Offering Of Securities For USD 150 Million 45
Hyperion Therapeutics Completes Public Offering Of Common Stock For USD 69 Million 46
Horizon Pharma Completes Public Offering Of Units For USD 86 Million 47
Hyperion Therapeutics Completes IPO For USD 57.5 Million 48
Horizon Pharma Completes Private Placement Of Units For USD 51 Million 49
Horizon Pharma Raises USD300 Million in Private Placement of 8.75% Notes Due 2024 50
Horizon Pharma Raises USD475 Million in Private Placement of 6.625% Notes Due 2023 51
Horizon Pharma Raises USD400 Million in Private Placement of 2.5% Senior Notes Due 2022 53
Horizon Pharma Completes Private Placement Of Notes Due 2018 For USD 150 Million 55
Clinigen Acquires Imukin from Horizon Pharma 56
Horizon Pharma May Sell its Primary Care Drugs Business 57
Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 58
Horizon Pharma Acquires River Vision Development 59
Horizon Pharma Acquires Raptor Pharma in Tender Offer 60
Horizon Pharma May Sell Equity Stake in The Company 62
Horizon Pharma Acquires Crealta for USD510 Million 63
Horizon Pharma Acquires Hyperion Therapeutics for USD1.1 Billion 64
Horizon Pharma Acquires Vidara Therapeutics International for USD660 Million in Reverse Acquisition 66
Horizon Pharma Plc, Key Competitors 68
Horizon Pharma Plc, Key Employees 69
Horizon Pharma Plc, Subsidiaries 70
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Horizon Pharma Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Horizon Pharma plc (Horizon Pharma) is a pharmaceutical company which develops and commercializes medical products for the treatment of pain, arthritis and inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. The company's marketed products include Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid 2%, Procysbi, Quinsair, Ravicti, Rayos and Vimovo. Horizon Pharma provides products and services to patients and healthcare professionals in the US. The company operates through offices in Illinois, California, Switzerland, the Netherlands and Germany. Horizon Pharma is headquartered in Dublin, Ireland.
Horizon Pharma Plc (HZNP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Horizon Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Horizon Pharma Acquires Worldwide Rights to Interferon Gamma-1b from Boehringer Ingelheim for USD28.2 Million 15
Horizon Pharma Acquires US Rights to Pennsaid 2% from Nuvo Research for USD45 Million 16
Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For USD 51 Million 18
Vidara Therapeutics International Acquires Actimmune From InterMune For USD 55 Million 20
Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 22
Venture Financing 23
River Vision Development Raises USD5 Million in Financing Round 23
River Vision Development Raises USD5.3 Million in Financing Round 24
River Vision Development Raises USD6 Million in Financing Round 25
River Vision Development Raises USD 17 Million In Series A Financing 26
Hyperion Therapeutics Raises USD 15 Million In Series D-II Financing 27
Private Equity 28
Vidara Therapeutics Raises Funds Through Private Equity Financing 28
Partnerships 29
Horizon Pharma Enters into Agreement with XL-protein 29
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 30
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 31
Clinigen Group Partners with Horizon Pharma 32
Horizon Pharma Enters into Agreement with Alliance for Lupus Research 33
Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 34
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 36
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 37
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 38
Licensing Agreements 40
Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 40
Horizon Pharma Enters into Licensing Agreement for Interferon Gamma-1b 41
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 42
Equity Offering 43
Horizon Pharma Raises USD499 million in Public Offering of Shares 43
Hyperion Therapeutics Files Registration Statement For Public Offering Of Securities For USD 150 Million 45
Hyperion Therapeutics Completes Public Offering Of Common Stock For USD 69 Million 46
Horizon Pharma Completes Public Offering Of Units For USD 86 Million 47
Hyperion Therapeutics Completes IPO For USD 57.5 Million 48
Horizon Pharma Completes Private Placement Of Units For USD 51 Million 49
Debt Offering 50
Horizon Pharma Raises USD300 Million in Private Placement of 8.75% Notes Due 2024 50
Horizon Pharma Raises USD475 Million in Private Placement of 6.625% Notes Due 2023 51
Horizon Pharma Raises USD400 Million in Private Placement of 2.5% Senior Notes Due 2022 53
Horizon Pharma Completes Private Placement Of Notes Due 2018 For USD 150 Million 55
Asset Transactions 56
Clinigen Acquires Imukin from Horizon Pharma 56
Horizon Pharma May Sell its Primary Care Drugs Business 57
Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 58
Acquisition 59
Horizon Pharma Acquires River Vision Development 59
Horizon Pharma Acquires Raptor Pharma in Tender Offer 60
Horizon Pharma May Sell Equity Stake in The Company 62
Horizon Pharma Acquires Crealta for USD510 Million 63
Horizon Pharma Acquires Hyperion Therapeutics for USD1.1 Billion 64
Horizon Pharma Acquires Vidara Therapeutics International for USD660 Million in Reverse Acquisition 66
Horizon Pharma Plc-Key Competitors 68
Horizon Pharma Plc-Key Employees 69
Horizon Pharma Plc-Locations And Subsidiaries 70
Head Office 70
Other Locations & Subsidiaries 70
Recent Developments 71
Financial Announcements 71
Nov 07, 2018: Horizon pharma reports third-quarter net sales growth of 20 percent driven by Orphan and Rheumatology net sales growth of 25 percent 71
Aug 08, 2018: Horizon pharma reports record quarterly net sales for orphan and rheumatology segment; increases full-year 2018 adjusted EBITDA guidance; implements new company operating structure to enhance focus on rare diseases 73
May 09, 2018: Horizon Pharma Reports Strong First-Quarter 2018 Orphan and Rheumatology Net Sales Growth 76
Feb 28, 2018: Horizon Pharma Announces Fourth-Quarter and Full-Year 2017 Results 79
Nov 06, 2017: Horizon Pharma Announces Third-Quarter and Year-to-Date 2017 Results 83
Aug 07, 2017: Horizon Pharma Announces Second-Quarter and Year-to-Date 2017 Results and Increases Full-Year 2017 Net Sales and Adjusted EBITDA Guidance 86
May 08, 2017: Horizon Pharma Announces First-Quarter 2017 Results and Revises Full-Year 2017 Net Sales and Adjusted EBITDA Guidance 90
Corporate Communications 93
Nov 30, 2017: Horizon Pharma Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer 93
Sep 11, 2017: Horizon Pharma Names Irina Konstantinovsky Executive Vice President, Chief Human Resources Officer 94
Aug 03, 2017: Horizon Pharma Appoints Pascale Witz and James Shannon, M.D. to Board of Directors 95
Other Significant Developments 96
Sep 27, 2018: The north american pediatric renal trials and collaborative studies and Horizon Pharma announce new long-term cystinosis registry 96
Jun 04, 2018: Horizon Pharma and the National Organization for Rare Disorders (NORD) Illustrate 35 years of Progress in Rare Disease at the Biotechnology Innovation Organization (BIO) International Convention 97
Jan 08, 2018: Horizon Pharma Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments 98
Mar 16, 2017: Horizon Pharma Announces "UCD in Common" for the Urea Cycle Disorder Community 101
Appendix 102
Methodology 102
About GlobalData 102
Contact Us 102
Disclaimer 102
List Of Figure
List of Figures
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
List Of Table
List of Tables
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Horizon Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Horizon Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Horizon Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Horizon Pharma Acquires Worldwide Rights to Interferon Gamma-1b from Boehringer Ingelheim for USD28.2 Million 15
Horizon Pharma Acquires US Rights to Pennsaid 2% from Nuvo Research for USD45 Million 16
Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For USD 51 Million 18
Vidara Therapeutics International Acquires Actimmune From InterMune For USD 55 Million 20
Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 22
River Vision Development Raises USD5 Million in Financing Round 23
River Vision Development Raises USD5.3 Million in Financing Round 24
River Vision Development Raises USD6 Million in Financing Round 25
River Vision Development Raises USD 17 Million In Series A Financing 26
Hyperion Therapeutics Raises USD 15 Million In Series D-II Financing 27
Vidara Therapeutics Raises Funds Through Private Equity Financing 28
Horizon Pharma Enters into Agreement with XL-protein 29
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 30
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 31
Clinigen Group Partners with Horizon Pharma 32
Horizon Pharma Enters into Agreement with Alliance for Lupus Research 33
Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 34
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 36
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 37
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 38
Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 40
Horizon Pharma Enters into Licensing Agreement for Interferon Gamma-1b 41
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 42
Horizon Pharma Raises USD499 million in Public Offering of Shares 43
Hyperion Therapeutics Files Registration Statement For Public Offering Of Securities For USD 150 Million 45
Hyperion Therapeutics Completes Public Offering Of Common Stock For USD 69 Million 46
Horizon Pharma Completes Public Offering Of Units For USD 86 Million 47
Hyperion Therapeutics Completes IPO For USD 57.5 Million 48
Horizon Pharma Completes Private Placement Of Units For USD 51 Million 49
Horizon Pharma Raises USD300 Million in Private Placement of 8.75% Notes Due 2024 50
Horizon Pharma Raises USD475 Million in Private Placement of 6.625% Notes Due 2023 51
Horizon Pharma Raises USD400 Million in Private Placement of 2.5% Senior Notes Due 2022 53
Horizon Pharma Completes Private Placement Of Notes Due 2018 For USD 150 Million 55
Clinigen Acquires Imukin from Horizon Pharma 56
Horizon Pharma May Sell its Primary Care Drugs Business 57
Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 58
Horizon Pharma Acquires River Vision Development 59
Horizon Pharma Acquires Raptor Pharma in Tender Offer 60
Horizon Pharma May Sell Equity Stake in The Company 62
Horizon Pharma Acquires Crealta for USD510 Million 63
Horizon Pharma Acquires Hyperion Therapeutics for USD1.1 Billion 64
Horizon Pharma Acquires Vidara Therapeutics International for USD660 Million in Reverse Acquisition 66
Horizon Pharma Plc, Key Competitors 68
Horizon Pharma Plc, Key Employees 69
Horizon Pharma Plc, Subsidiaries 70
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Horizon Pharma Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020